questionText: To ask the Secretary of State for Health and Social Care, if she will make an estimate of when the approval process for the use of Xywav to treat idiopathic hypersomnia will be completed.
answerText: The Medicines and Healthcare products Regulatory Agency (MHRA) has not issued a marketing authorisation (MA) for Xywav. Should a MA application be received, the MHRA has procedures in place to review it, such as the 150 Day National procedure or the Inter...
heading: Idiopathic Hypersomnia: Drugs